Fig. 3

PSTK knockout sensitizes HCC cells to targeted therapy in vitro. A PSTK was knocked out in Hep3B, Huh7, HepG2, and SNU-398 cells, with Western blotting being used to confirm the efficiency of knockout. B PSTK-KO cells and control sgRNA transfected cells were treated for 48 h with a range of Abemaciclib/Sorafenib/Erastin doses, after which a CCK-8 assay was used to assess cell viability relative to vehicle-treated cells (n=5). C PSTK-KO cells and control sgRNA-transfected cells were treated for 48 h with Abemaciclib (5 μM), Sorafenib (5 μM), or Erastin (10 μM), after which an LDH assays were used to assess cell death (n=3). D Colony formation assays were conducted by plating PSTK-KO or control cell lines (800 cells/well) and treating them with Abemaciclib (2 μM), Sorafenib (2 μM), Erastin (5 μM), or vehicle control for 10 days (n=3). *p<0.05; **p<0.01; ***p<0.001; Student’s t-test